In a research note titled "Not Too Hot, Not Too Cold, Things Are Just Right at TXMD," Cantor Fitzgerald analyst Louise Chen keeps an Overweight rating on TherapeuticsMD with a $27 price target. The FDA released its "2018 Compounding Policy Priorities Plan," which underscores the "large and underappreciated" market opportunity for TherapeuticsMD' Bijuva, Chen tells investors in a research note. She points out that one of the priorities listed by the FDA includes: "Restricting Compounding of Drugs that are Essentially Copies of FDA-Approved Drugs." This is positive for Bijuva, says Chen. The analyst thinks the peak sales potential for the drug is $1B-plus.